Related Articles

• Pegylated liposomal doxorubicin: Pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (Review)
• Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.
• Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a Phase II study
• Pegylated liposomal doxorubicin for platinum-resistant or refractory Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience
• Phase I study of nanoparticle albumin-bound paclitaxel, carboplatin and trastuzumab in women with human epidermal growth factor receptor 2-overexpressing breast cancer